通过细菌细胞壁激活来自耐美西林金黄色葡萄球菌 (Staphylococcus aureus) 的青素结合蛋白2a进行催化
Cosimo Fuda1, Dusan Hesek, Mijoon Lee
1Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, USA.
Journal of the American Chemical Society
|February 17, 2005
概括
耐甲基西林黄金葡萄球菌 (MRSA) 使用一种独特的蛋白质,PBP 2a,抵抗抗生素. 细菌细胞壁碎片与PBP 2a结合,只有在细胞壁的基本修复过程中才能向抗生素揭示其活性部位.
科学领域:
- 微生物学 微生物学
- 结构生物学 结构生物学
- 药物发现 药物发现 药物发现
背景情况:
- 甲素耐药黄金葡萄球菌 (MRSA) 构成了严重的公共卫生威胁.
- MRSA对β-lactam抗生素的耐药性是由独特的青素结合蛋白,PBP 2a.介导的.
- PBP 2a活性部位表现出封闭的形状,阻碍了抗生素的结合.
研究的目的:
- 为了研究PBP 2a功能和抗性的机制.
- 了解PBP 2a如何与其生理基质相互作用.
- 为了确定MRSA的抗药机制中的潜在漏洞.
主要方法:
- 进行X射线晶体学以确定PBP 2a结构.
- 使用合成细菌细胞壁碎片进行结合试验.
- 在基质结合时对PBP 2a进行符合性分析.
主要成果:
- PBP 2a的活性部位在形状上是灵活的.
- 细菌细胞壁碎片与PBP 2a结合以和性.
- 细胞壁碎片的结合会诱导形状变化,打开PBP 2a活性部位.
结论:
- MRSA采用一种新的机制来保护PBP 2a免受抗生素的侵害.
- PBP 2a活性部位被屏蔽,直到细胞壁合成需要其功能.
- 这一规范性法规为针对MRSA的新型抗生素开发提供了潜在的目标.
相关概念视频
Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...


